Injective jumps 27% in a day, leaving NEAR and Sei behind
INJ's surge highlights potential market shifts as ETF approvals could broaden investor access, impacting supply dynamics and valuation.
New to markets — prices, yields, market cap? We explain every term as you browse, in plain English. Same data, with the help built in.
You already know the market. Just the data — clean, fast and compact, with no extra explanations. This is the default view.
Every figure on this site is available as JSON, with its period and source attached.
Read the API docsInjective is a Layer 1 blockchain built specifically for decentralized finance applications, sitting within the Cosmos, Ethereum, and Solana ecosystems among others. It aims to give developers ready-made financial infrastructure modules so they can build products such as decentralized exchanges, prediction markets, and lending protocols without constructing those components from scratch. The intended users are both DeFi developers who want a purpose-built foundation and the end users of the applications built on top of it.
Injective is an interoperable chain that bridges EVM-compatible networks like Ethereum and non-EVM networks like Solana through decentralized cross-chain infrastructure, allowing assets and messages to move across ecosystems. The INJ token functions inside the network as the native asset, and because the fully diluted valuation equals the market capitalization and 100 percent of the circulating supply is already issued against a null maximum supply, there is no further scheduled token emission creating dilution. The consensus algorithm and block time are not recorded in the data held by this site.
Injective generated fees of 8,038 USD in the most recent 24-hour period, 56,253 USD over the trailing 7 days, and 234,224 USD over the trailing 30 days, which annualizes to approximately 2,849,725 USD based on that 30-day window. The take rate for the trailing 30 days is recorded at 100 percent, meaning the protocol retains all fees collected rather than distributing a portion to a separate supplier side, a point confirmed by the supply-side revenue figure of zero for the same period. Fee growth over the trailing 30 days stands at 18.54 percent. The market capitalization relative to annualized fees sits at 253.43, a ratio that simply describes the relationship between the network's current size and its recent fee output.
Written from the figures on this page by an AI language model and reviewed against them. It contains no view on price.
INJ's surge highlights potential market shifts as ETF approvals could broaden investor access, impacting supply dynamics and valuation.
Injective continued its rebound on Friday, trading around $9.25 as improving momentum and declining exchange balances supported a constructive outlook.
Long-term investors will want to see prices climb past $13.575 comfortably before looking for signs of a long-term trend shift.
Injective has rallied more than 8% on October 16, reaching $9.35 as increased trading activity and renewed interest in the network's institutional developments have…
Injective records significant gains as Gulf Labs joined its institutional validators with its trading volume and open interest spiking sharply recently.